Allarity Therapeutics, Inc. has announced the expansion of their Phase 2 clinical trial for stenoparib, a dual PARP/Wnt pathway inhibitor, aimed at treating advanced ovarian cancer. Their recent decision seeks to accelerate the drug's clinical development and work towards FDA regulatory
The human gut microbiome plays a crucial role in overall health, influencing everything from digestion to immune function. Recent advancements in proteo-genomics have provided unprecedented insights into the complex interactions within the gut microbiome. A groundbreaking study has utilized
In the rapidly evolving landscape of biopharmaceutical manufacturing, capturing real-time data has become pivotal in optimizing bioreactor performance and producing high-quality products. Inline monitoring technologies are at the forefront of this transformation, offering real-time surveillance and
The cell culture media market is experiencing a significant surge, driven by technological advancements and increased investments in research and development (R&D). These media are crucial for the growth, proliferation, and maintenance of various cell types, including microbial cells and stem
The search for effective treatments for Parkinson's disease has been long and arduous, with researchers globally dedicating countless hours to uncover potential therapies. One promising candidate, exenatide, a GLP-1 drug traditionally used to treat Type 2 diabetes, recently underwent scrutiny
Researchers at the University of Kentucky have pioneered a groundbreaking microscopy technique that may offer an affordable and effective way to study cancer cell metabolism. This innovative method, which focuses on observing metabolic reprogramming within cancer cells, has the potential to
A recent study published in the American Society of Hematology's journal, Blood, has dispelled the long-held belief that sickle cell trait (SCT) can lead to sudden death, particularly under conditions of physical exertion. This misconception has disproportionately affected Black males with
On Thursday, the Food and Drug Administration approved Journavx, a highly anticipated non-opioid pain medication developed by Vertex Pharmaceuticals, marking a significant milestone in the effort to shift pain treatment away from opioids. This new drug has been initially approved to treat acute
Basal cell carcinoma (BCC) is the most common cancer worldwide, with its incidence doubling over the past 20 years. Traditional treatments, primarily surgical excision, come with a recurrence risk and potential complications. This article explores the potential of Talimogene laherparepvec (T-VEC),
Tuberculosis (TB) remains one of the deadliest infectious diseases worldwide, with drug-resistant strains posing a significant challenge to global health. Recent advancements in TB treatment, particularly for drug-resistant forms, offer new hope. This article explores the potential of new drug
